Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    24077916 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Biological: trastuzumab;   Drug: Neratinib

Indicates status has not been verified in more than two years